Janssen Biotech to Acquire Oncolytic Virus Company BeneVir for US$1.04 B
By Natasha Berry
Pharma Deals Review: Vol 2018 Issue 5 (Table of Contents)
Published: 24 May-2018
DOI: 10.3833/pdr.v2018.i5.2327 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Dedicated to pipeline expansion in immuno-oncology, Janssen Biotech (a division of Johnson & Johnson) has entered into a definitive agreement to acquire the oncolytic virus company, BeneVir Biopharm, for a sum of US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS